Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

6.21
+0.47008.19%
Post-market: 6.250.0400+0.64%18:03 EDT
Volume:1.02M
Turnover:6.18M
Market Cap:319.75M
PE:-1.70
High:6.28
Open:5.70
Low:5.70
Close:5.74
Loading ...

Verastem Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
21 Mar

Verastem Q4 Adj $(0.60) Beats $(0.81) Estimate

Benzinga
·
21 Mar

Verastem reports Q4 EPS (60c), consensus (74c)

TIPRANKS
·
21 Mar

Verastem Inc: Qtrly Adj Loss per Share $0.60

THOMSON REUTERS
·
21 Mar

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Business Wire
·
21 Mar

Verastem Inc expected to post a loss of 81 cents a share - Earnings Preview

Reuters
·
14 Mar

Verastem Inc expected to post a loss of 81 cents a share - Earnings Preview

Reuters
·
10 Mar

Verastem Is Maintained at Buy by B. Riley Securities

Dow Jones
·
01 Feb

B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating

MT Newswires Live
·
31 Jan

Verastem Inc : B. Riley Raises Target Price to $9 From $7

THOMSON REUTERS
·
31 Jan

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Business Wire
·
29 Jan

Mizuho Securities Sticks to Its Buy Rating for Verastem (VSTM)

TIPRANKS
·
24 Jan

RBC Capital reiterates Outperform after Verastem formalizes key 2025 priorities

TIPRANKS
·
24 Jan

Verastem Expands Oncology Pipeline with VS-7375 Acquisition

TIPRANKS
·
23 Jan

Verastem Inc - Potential U.S. Commercial Launch for Avutometinib Plus Defactinib Mid-2025

THOMSON REUTERS
·
23 Jan

Verastem Inc - VS-7375 on Track for U.S. Ind Filing in Q1 2025

THOMSON REUTERS
·
23 Jan

Verastem Inc - Updated Data for Ramp 205 Trial Expected in Q1 2025

THOMSON REUTERS
·
23 Jan

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting Ras/Mapk Pathway-Driven Cancers

THOMSON REUTERS
·
23 Jan

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Business Wire
·
23 Jan

Verastem Appoints Matthew E. Ros as COO

TIPRANKS
·
22 Jan